Introduction

The COVID-19 pandemic diverted global attention toward the biotech and pharma industries, and the cell and gene therapy sector had found itself in a convenient position to produce vaccines and treatments in the fight against the virus. However, these new opportunities have not come without obstacles, as regional lockdowns and added safety precautions around the world have threatened research, logistics and supply. In February 2021, Informa Connect conducted a global survey to find out what innovation has been developing across the cell and gene therapy space in response to the pandemic. Based on responses from 92 cell and gene therapy professionals, this final report reveals the biggest challenges faced by companies in the space, the most significant financial shifts and what new strategies have been adopted across research, supply chains, manufacturing and partnering.

Top-level Findings

78% of respondents said that they believe the pandemic has benefitted investment in the cell and gene therapy sector.
44% of respondents said that the COVID-19 pandemic had significant impact on their raw and ancillary materials and supply chain.
63% of respondents said that the pandemic had caused them to re-evaluate or change their manufacturing or supply strategies.
52% of respondents said that their companies’ partnering and licensing activities had increased since the COVID-19 pandemic began.